Pregled bibliografske jedinice broj: 1060741
Insulin-like growth factor 2 binding protein 3 expression on endoscopic ultrasound guided fine needle aspiration specimens in pancreatic ductal adenocarcinoma
Insulin-like growth factor 2 binding protein 3 expression on endoscopic ultrasound guided fine needle aspiration specimens in pancreatic ductal adenocarcinoma // European journal of gastroenterology & hepatology, 32 (2020), 4; 496-500 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1060741 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Insulin-like growth factor 2 binding protein 3
expression on endoscopic ultrasound guided fine
needle aspiration specimens in pancreatic ductal
adenocarcinoma
Autori
Tadić , Mario ; Štoos-Veić Tajana ; Kujundzic , Milan ; Turčić , Petra ; Aralica , Gorana ; Boskoski, Ivo
Izvornik
European journal of gastroenterology & hepatology (0954-691X) 32
(2020), 4;
496-500
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
IMP 3 ; EUS-FNA ; PDAC ; immunocytochemistry
(IMP-3 ; EUS-FNA ; PDAC ; immunocytochemistry)
Sažetak
Background: Despite numerous investigations, we still do not have a specific marker for pancreatic ductal adenocarcinoma. Only guideline- recommended biomarker for pancreatic ductal adenocarcinoma is the CA19-9, but it is also present in other gastrointestinal diseases. IMP3 is a new potential biomarker that is over- expressed in some cancers. The aims of our study were (1) to assess IMP3 in benign pancreatic lesions and pancreatic cancer, and (2) to estimate its concentrations in localized and advanced pancreatic cancer. Patients and methods: Seventy-five patients with solid pancreatic lesions who underwent EUS-FNA were included. Patients were divided into three groups: benign lesions, cancer localized only on the pancreas, and patients with advanced pancreatic cancer (locally advanced or with distal metastases). Immunoreactivity of IMP3 was assessed on cytological smears sampled by endoscopic ultrasound. Results: IMP3 was expressed in 89% of the patients with pancreatic cancer and not in benign lesions. Stronger expression of IMP3 protein and stage of the pancreatic cancer was statistically significant. IMP3 was expressed in all localized cancers and in 85% of patients with advanced pancreatic cancer. In the subgroup with locally advanced cancer, IMP3 was expressed in 88%, and in 83% of patients in the subgroup with distal metastasis (P = 0.007). In the present study, sensitivity was 89%, specificity 100%, with positive predictive value of 100% and negative predictive value of 63%. Conclusion: There is a positive correlation between IMP3 expression and TNM stages of the pancreatic cancer. Higher expression of IMP3 on EUS-FNA specimens can suggest poorer prognosis.
Izvorni jezik
Engleski
Znanstvena područja
Farmacija
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava",
Medicinski fakultet, Osijek
Profili:
Mario Tadić
(autor)
Milan Kujundžić
(autor)
Gorana Aralica
(autor)
Petra Turčić
(autor)
Tajana Štoos-Veić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE